肺金生方联合吉非替尼治疗晚期非小细胞肺癌的临床疗效  

Clinical efficacy of Feijinsheng Recipe combined with gefitinib in the treatment of advanced non-small cell lung cancer

作　　者：姚成 陈滨海 高文仓 陈冬 俞森权 庞德湘 陈卫建 YAO Cheng;CHEN Binhai;GAO Wencang;CHEN Dong;YU Senquan;PANG Dexiang;CHEN Weijian(Department of Oncology,the Second Affiliated Hospital of Zhejiang Chinese Medical University,Hangzhou310005,China)

机构地区：[1]浙江中医药大学附属第二医院肿瘤科,浙江杭州310005

出　　处：《中国现代医生》2022年第1期98-102,共5页China Modern Doctor

基　　金：浙江省中医药科技计划项目(2021ZB125,2020ZB116,2019ZB050,2019ZZ011)。

摘　　要：目的 观察肺金生方加减与EGFR-TKIs联合治疗晚期非小细胞肺癌的临床疗效。方法 选取2016年10月至2018年12月在浙江中医药大学附属第二医院就诊的90例EGFR突变晚期非小细胞肺癌患者随机分为治疗组(46例)和对照组(44例)。对照组给予吉非替尼靶向药物治疗,治疗组给予吉非替尼靶向药物联合肺金生方治疗,服药后0、1、3、6个月观察两组患者的临床疗效、血清肿瘤标志物、免疫功能、生存质量、中医证候及不良反应等方面的变化。结果 治疗后,治疗组的疾病控制率为86.96%,对照组为75.0%,差异有统计学意义(P<0.05)。两组患者治疗后的CEA、CYFRA21-1均较治疗前明显下降(P<0.05)。治疗3个月后,治疗组的CD3^(+)为(68.90±10.34)%、CD4^(+)为(41.29±8.36)%,均高于对照组(P<0.05)。与对照组比较,治疗后治疗组患者的中医症候积分、生存质量卡氏评分及不良反应发生率明显降低(P<0.05)。结论 肺金生方联合吉非替尼治疗晚期NSCLC临床疗效较好,且能提升患者生存质量,降低不良反应发生率。Objective To observe the clinical efficacy of modified Feijinsheng recipe combined with EGFR-TKIs in the treatment of advanced non-small cell lung cancer(NSCLC).Methods A total of 90 patients with advanced NSCLC with EGFR mutation admitted to the Second Affiliated Hospital of Zhejiang Chinese Medical University from October 2016 to December 2018 were selected as objects.They were randomly divided into the treatment group(46 cases)and the control group(44 cases).The control group was treated with gefitinib targeted drugs,while the treatment group was treated with gefitinib targeted drugs combined with Feijinsheng recipe.The clinical efficacy,serum tumor markers,immune function,quality of life,traditional Chinese medicine(TCM)syndromes and adverse reactions(ADRs)of the two groups were observed at 0,1,3 and 6 months after taking drug.Results After treatment,the disease control rate of the treatment group was 86.96%and that of the control group was 75.0%.The difference between the two groups was statistically significant(P<0.05).The CEA and CYFRA21-1 of the two groups of patients after treatment were significantly lower than those before treatment(P<0.05).After 3 months of treatment,the CD3^(+)of the treatment group was(68.90±10.34)%and the CD4^(+)was(41.29±8.36)%,which were higher than those of the control group(P<0.05).Compared with the control group,the TCM syndrome score,the quality of life Karnofsky score and the incidence of adverse reactions were significantly reduced in the treatment group after treatment(P<0.05).Conclusion Feijinsheng recipe combined with gefitinib can achieve better clinical efficacy than gefitinib alone in the treatment of advanced NSCLC,it can improve the immunity of patients,help to improve the quality of life of patients,and reduce the incidence of ADRs.

关 键 词：肺癌 肺金生方 EGFR-TKIS 吉非替尼 

分 类 号：R734.2[医药卫生—肿瘤]